Document:

ESCROW AGREEMENT

     THIS  ESCROW  AGREEMENT  is made and entered into on August 29, 2007 by and
between  MED-X  SYSTEMS, INC., a Nevada corporation ("Med-X"), EQUITABLE ASSETS,
INC.,  a  Nevada  corporation,  the controlling stockholder of Med-X (the "Med-X
Controlling  Stockholder"),  CRANSTON,  INC.,  a  Nevada  corporation  (the
"Subsidiary"), CRANSTON, INC., a New York corporation ("Cranston"), the Cranston
stockholders  being  more  fully  described  on  the  signature page hereof (the
"Cranston  Stockholders"),  and  GLAST,  PHILLIPS  &  MURRAY,  P.C. (the "Escrow
Agent").

     WHEREAS,  Cranston and the Cranston Stockholders and Med-X, the Subsidiary,
and  the  Med-X  Controlling  Stockholder  have  executed  that certain Plan and
Agreement  of  Triangular  Merger between Med-X Systems, Inc., Cranston, Inc., a
Nevada corporation, and Cranston, Inc., a New York corporation, dated August 29,
2007  (the  "Merger  Agreement");  and

     WHEREAS,  all  capitalized  terms  herein  shall  have the same meanings as
defined  in  the  Merger  Agreement,  unless  otherwise  defined  herein;  and

     WHEREAS,  the  Cranston  Stockholders  have  delivered into escrow with the
Escrow  Agent  the  sum  of  $80,000  (the  "Escrowed  Funds");  and

     WHEREAS,  4,188,646  shares  of  the  Med-X Common Stock owned by the Med-X
Controlling  Stockholder,  together  with  all  shares  issued  in  exchange for
converted debt, have been delivered to the Escrow Agent (the "Escrowed Shares");

     NOW,  THEREFORE, in consideration of the foregoing and the following mutual
covenants  and  agreements,  the  parties  hereto  do  agree  as  follows:

     1.     Transfer  into Escrow  by  the  Cranston  Stockholders.  The
            ------------------------------------------------------
Cranston  Stockholders  have  delivered  the Escrowed Funds into escrow with the
Escrow  Agent,  the receipt of which is hereby acknowledged by the Escrow Agent.

     2.     Transfer  into Escrow by the Med-X Controlling Stockholder.  The
            ----------------------------------------------------------
Med-X Controlling Stockholder has delivered the Escrowed Shares into escrow with
the  Escrow  Agent,  the  receipt  of which is hereby acknowledged by the Escrow
Agent.

     3.     Release of the Escrowed  Funds.  Promptly  following  the  Effective
            ------------------------------
Date,  the  Med-X  Controlling  Stockholder  will use its best efforts to do all
things  necessary  to qualify the shares of the Med-X Common Stock for quotation
and  sale  on the Over the Counter Bulletin Board maintained by the Nasdaq Stock
Market,  Inc. (the "OTCBB"). The Escrowed Funds shall be held in escrow with the
Escrow  Agent until such time as the shares of the Med-X Common Stock are quoted
for  sale  on  the  OTCBB.  Immediately  upon  receiving  notice  from the Med-X
Controlling  Stockholder  and  the  Cranston  Stockholders  that  the  OTCBB has
notified all parties to the Merger Agreement that the shares of the Med-X Common
Stock  are  being quoted for sale on the OTCBB and are trading on the OTCBB, the
Escrow  Agent  shall  deliver  the  Escrowed  Funds  to  the  Med-X  Controlling
Stockholder.  In the event that Med-X is unable to procure a trading symbol from
the  NASD, due to NASD rejection, within 180 days from the date of the execution
of  this  agreement,  either Cranston or the Med-X Controlling Shareholder shall
have  the  right  to  terminate  this agreement upon ten (10) days notice to the
other  party.

     4.     Release  of  the Escrowed Shares.  The Med-X Controlling Stockholder
            --------------------------------
agrees  that  the  Escrowed  Shares  may  not  be sold for a period of 12 months
following  the  Effective  Date.  Thereafter, the Escrow Agent shall release the
Escrowed  Shares  to the Med-X Controlling Stockholder in such amounts which may
then  be  sold pursuant to the provisions of Rule 144(e) promulgated pursuant to
the  Securities  Act  of  1933,  as  amended.

     5.     Duty  of the Escrow Agent.  The sole duty of the Escrow Agent, other
            -------------------------
than  as  hereinafter  specified, shall be to receive the Escrowed Funds and the
Escrowed  Shares  and  hold  them  subject  to  release, in accordance with this
Agreement,  the  Merger  Agreement,  and  the  Other  Agreements.

     6.     Liability  of  the  Escrow  Agent.  The  duties  of the Escrow Agent
            ---------------------------------
hereunder  will  be  limited  to  observance  of  the express provisions of this
Agreement.  Furthermore,  the  Escrow  Agent  is  not  expected  or  required

                                       1
<PAGE>
to  be  familiar  with  the  provisions  of  any other writing, understanding or
agreement,  and  shall  not  be  charged with any responsibility or liability in
connection with the observance or non-observance of the provisions of such other
writing,  understanding  or  agreement,  and  no  implied  covenant  of any type
whatsoever  shall  be  read  into  this  Agreement.

     The  further  provisions  shall  govern  the  Escrow  Agent's  liabilities
hereunder:

          (a)     In  receiving  the Escrowed Funds and the Escrowed Shares, the
Escrow  Agent  acts  only as a depository and thereby assumes no responsibility,
except  pursuant  to  the  terms  of  this  Agreement.

          (b)     The  Escrow Agent may act or refrain from acting in respect of
any  matter  covered by this Agreement in full reliance upon and with the advice
of  counsel  which  may  be  selected  by it, and shall be fully protected in so
acting  or  in  refraining  from  acting  upon  the  advice  of  such  counsel.
Furthermore, the Escrow Agent may rely and shall be protected in acting upon any
writing  that  may  be  submitted  to it in connection with its duties hereunder
without determining the genuineness, authenticity or due authority from any such
writing or the person signing same and shall have no liability or responsibility
with  respect  to  the  form,  content  or  validity  thereof.

          (c)     The Escrow Agent shall have no responsibility or liability for
any  act  or  omission  on its part, notwithstanding any demand or notice to the
contrary  by  the Med-X Controlling Stockholder or the Cranston Stockholders, or
any  other  person or entity, all subject to the sole limitation that the Escrow
Agent exercises its best judgment.  Except as herein expressly provided, none of
the  provisions  of  this  Agreement shall require the Escrow Agent to expend or
risk  its  own  funds  or  otherwise incur financial liability or expense in the
performance  of  any  of  its  duties  hereunder.

          (d)     The  Escrow Agent is hereby authorized to comply with and obey
all  orders,  judgments, decrees or writs entered or issued by any court, and in
the  event  the  Escrow  Agent  obeys or complies with any such order, judgment,
decree  or  writ,  in  whole  or  in  part,  it shall not be liable to the Med-X
Controlling  Stockholder,  the  Cranston  Stockholders,  or  any other person or
entity,  by  reason  or  such  compliance,  notwithstanding  that  it  shall  be
determined  that  any  such  order, judgment, decree or writ was entered without
jurisdiction  or  was  invalid  for  any  reason  or  is  subsequently reversed,
modified,  annulled,  satisfied  or  vacated.

          (e)     The  Escrow Agent shall not be required to institute or defend
any action or legal process involving any matter referred to herein which in any
manner affects its duties or liabilities hereunder to take any other action with
reference  to the Escrowed Funds and the Escrowed Shares not specifically agreed
to  herein, and the Escrow Agent shall not be responsible for any act or failure
to  act  on  its  part  except in the case of its own fraud or gross negligence.

          (f)     Should  any  controversy  arise  between the Escrow Agent, the
Med-X  Controlling  Stockholder, the Cranston Stockholders, or between any other
person  or  entity  with  respect  to  this  Agreement,  or  with respect to the
ownership of or the right to receive the Escrowed Funds and the Escrowed Shares,
the Escrow Agent shall have the right to institute a plea of interpleader in any
court  of competent jurisdiction to determine the rights of the parties.  Should
a plea of interpleader be instituted, or should the Escrow Agent become involved
in  litigation  in  any  manner  whatsoever connected with or pertaining to this
Agreement, the Merger Agreement, the Other Agreements, or the Escrowed Funds and
the  Escrowed  Shares,  the  Med-X  Controlling  Stockholder  and  the  Cranston
Stockholders hereby agree to pay the Escrow Agent, on demand, in addition to any
charge  made  hereunder  for  acting as escrow agent, reasonable attorneys' fees
incurred  by  the  Escrow  Agent, and any other disbursements, expenses, losses,
costs,  and  damages  in  connection  with  or  resulting  from such litigation.

     7.     Indemnification.  The Med-X Controlling Stockholder and the Cranston
            ---------------
Stockholders  hereby  agree to indemnify and hold the Escrow Agent harmless from
and  against  any  and  all  claims,  loses,  liabilities, costs, damages, fees,
charges,  and  expenses  (including  attorneys' fees) which the Escrow Agent may
incur  or  sustain  by  reason  of  its  acting  as  the Escrow Agent under this
Agreement,  unless  same  shall result from the fraud or gross negligence of the
Escrow  Agent.

                                       2
<PAGE>
     8.     Death,  Incapacity, or Resignation of the Escrow Agent.  In the
            -----------------------------------------------------
event  of  the  death, incapacity, or resignation of the Escrow Agent, the Med-X
Controlling  Stockholder and the Cranston Stockholders shall appoint a successor
Escrow Agent within 10 days following such death, incapacity, or resignation. If
the  Med-X  Controlling  Stockholder and the Cranston Stockholders shall fail to
appoint  a  successor  Escrow  Agent  within  such  10  day  period,  the  Med-X
Controlling  Stockholder  may  thereupon  deposit  the  Escrowed  Funds  and the
Escrowed Shares into the registry of a court of competent jurisdiction, and seek
to  have a successor Escrow Agent appointed by such court. Any substitute Escrow
Agent  appointed  hereunder  shall possess and exercise all powers and authority
herein  conferred  on  the  original  Escrow  Agent,  unless the court otherwise
decrees  in  the order of appointment. Further, any successor Escrow Agent shall
receive such compensation as such court may determine. The parties hereto intend
that  a  substitute  Escrow Agent will be appointed to fulfill the duties of the
Escrow  Agent hereunder for the remaining term of this Agreement in the event of
the  Escrow Agent's death, incapacity, or resignation, and the Med-X Controlling
Stockholder  and  the  Cranston  Stockholders  will  use  their  best efforts to
promptly  appoint  a substitute Escrow Agent who shall be bound by the terms and
provisions  of  this  Agreement.

     9.     Termination  and  Amendment.  This  Agreement shall remain in effect
            ---------------------------
until  the  Escrowed  Funds  and the Escrowed Shares are delivered in accordance
herewith;  provided  that  any  Escrow Agent hereunder who resigns in accordance
with  the  terms  hereof  shall  no  longer be bound by this Agreement, but this
Agreement,  including, but not limited to the indemnification provisions hereof,
shall  remain  in  effect,  notwithstanding  such  resignation,  for purposes of
determining  the  rights  and  duties  of the Med-X Controlling Stockholder, the
Cranston  Stockholders,  the  Escrow  Agent, and any successor Escrow Agent.  No
amendment  or  modification to this Agreement shall be in force or effect unless
signed  by  the  parties  hereto.

     10.     No Trusteeship.  The Med-X Controlling Stockholder and the Cranston
             --------------
Stockholders  agree  that  the  Escrow  Agent  is  acting  solely as an escrowee
hereunder  and  not  as  a  trustee  and  that the Escrow Agent has no fiduciary
duties,  obligations  or  liabilities  under  this  Agreement.

     11.     Confidentiality.  Except  as  required  by  applicable  law,  legal
             ---------------
process  or  other legal compulsion, the Escrow Agent shall hold all information
relating to the transactions contemplated by this Agreement in strict confidence
and  under  no  circumstance  shall  any  of  the  terms  and  conditions or the
participants  involved  be  disclosed,  unless  such  disclosure  is mandated by
applicable  law.

     12.     Mediation and Arbitration.  All disputes arising or related to this
             -------------------------
Agreement  must  exclusively  be  resolved  first  by  mediation with a mediator
selected  by  the  parties,  with  such  mediation to be held in Houston, Harris
County, Texas.  If such mediation fails, then any such dispute shall be resolved
by  binding  arbitration  under the Commercial Arbitration Rules of the American
Arbitration  Association  in  effect  at  the  time  the  arbitration proceeding
commences, except that (a) Texas law and the Federal Arbitration Act must govern
construction  and  effect, (b) the locale of any arbitration must be in Houston,
Harris County, Texas, and (c) the arbitrator must with the award provide written
findings  of  fact  and  conclusions of law.  Any party may seek from a court of
competent  jurisdiction  any provisional remedy that may be necessary to protect
its rights or assets pending the selection of the arbitrator or the arbitrator's
determination  of  the  merits  of  the  controversy.  The  exercise  of  such
arbitration  rights by any party will not preclude the exercise of any self-help
remedies  (including  without  limitation, setoff rights) or the exercise of any
non-judicial  foreclosure  rights.  An  arbitration  award may be entered in any
court  having  jurisdiction.

     13.     Attorneys'  Fees.  In the event that it should become necessary for
             ----------------
any  party  entitled  hereunder  to  bring  suit  against  any  other  party for
enforcement  of  the covenants contained herein, the parties hereby covenant and
agree  that  the  party  who is found to be in violation of this Agreement shall
also be liable to the other parties for all reasonable attorneys' fees and costs
of  court  incurred  by  such  other  parties.

     14.     Benefit.  The  terms  and  provisions  of  this  Agreement shall be
             -------
binding  upon, inure to the benefit of and be enforceable by, the parties hereto
and  their  respective  successors  and  permitted  assigns.

     15.     Notices.  All  notices, requests, demands, and other communications
             -------
hereunder  shall be in writing and delivered personally or sent by registered or
certified  United States mail, return receipt requested with postage prepaid, or
by  telecopy  or e-mail, if to Med-X, the Med-X Controlling Stockholder, and the
Subsidiary,  addressed  to

                                       3
<PAGE>
Mr.  Hank  A.  Vanderkam  at  1301  Travis,  Suite  1200,  Houston, Texas 77002,
telephone  (713) 547-8900, telecopier (713) 547-8910, and e-mail hpv@v-slaw.com;
and  if to Cranston and the Cranston Stockholders, addressed to Mr. Alan Moadel,
2  West  46th  Street,  Second  Floor, New York, New York 10036, telephone (800)
930-8780,  and  email  alan@epilx.com;  and if to the Escrow Agent, addressed to
Norman T. Reynolds, Esq. at 815 Walker Street, Suite 1250, Houston, Texas 77002,
telephone  (713)  237-3135,  telecopier  (713)  237-3202,  and  e-mail
nreynolds@gpm-law.com.  Any  party  hereto  may change its address upon 10 days'
written  notice  to  any  other  party  hereto.

     16.     Construction.  Words  of any gender used in this Agreement shall be
             ------------
held and construed to include any other gender, and words in the singular number
shall be held to include the plural, and vice versa, unless the context requires
otherwise.  In addition, the pronouns used in this Agreement shall be understood
and  construed  to  apply  whether  the  party  referred  to  is  an individual,
partnership,  joint  venture,  corporation or an individual or individuals doing
business  under  a  firm  or  trade name, and the masculine, feminine and neuter
pronouns  shall  each include the other and may be used interchangeably with the
same  meaning.

     17.     Waiver.  No  course  of  dealing on the part of any party hereto or
             ------
its agents, or any failure or delay by any such party with respect to exercising
any  right,  power  or  privilege  of  such  party  under  this Agreement or any
instrument  referred to herein shall operate as a waiver thereof, and any single
or partial exercise of any such right, power or privilege shall not preclude any
later  exercise  thereof  or any exercise of any other right, power or privilege
hereunder  or  thereunder.

     18.     Representations,  Warranties  and  Agreements  to  Survive.  All
             ----------------------------------------------------------
indemnity  agreements  set  forth  in  this  Agreement,  as  well  as  all
representations,  warranties,  covenants  and other agreements set forth in this
Agreement shall remain operative and in full force and effect at the termination
of  this  Agreement,  and  any successor of the parties shall be entitled to the
benefit  of  the  respective  representations,  warranties  and  agreements made
herein.

     19.     Cumulative  Rights.  The  rights  and  remedies  contained  in this
             ------------------
Agreement  shall  be cumulative and the exercise or partial exercise of any such
right  or  remedy  shall not preclude the exercise of any other right or remedy.

     20.     Invalidity.  In  the  event  any  one  or  more  of  the provisions
             ----------
contained  in this Agreement or in any instrument referred to herein or executed
in  connection herewith shall, for any reason, be held to be invalid, illegal or
unenforceable  in  any respect, such invalidity, illegality, or unenforceability
shall  not  affect  the  other  provisions  of  this Agreement or any such other
instrument.

     21.     Headings.  The  headings used in this Agreement are for convenience
             --------
and reference only and in no way define, limit, amplify or describe the scope or
intent  of  this  Agreement,  and  do  not  affect  or constitute a part of this
Agreement.

     22.     Excusable Delay.  The parties shall not be obligated to perform and
             ---------------
shall  not  be  deemed  to  be  in  default  hereunder,  if the performance of a
non-monetary obligation required hereunder is prevented by the occurrence of any
of  the  following,  other  than as the result of the financial inability of the
party  obligated  to  perform: acts of God, strikes, lock-outs, other industrial
disturbances,  acts  of  a public enemy, war or war-like action (whether actual,
impending  or  expected  and  whether  de jure or de facto), acts of terrorists,
arrest  or  other  restraint  of  government  (civil  or  military),  blockades,
insurrections,  riots,  epidemics,  landslides,  lightning,  earthquakes, fires,
hurricanes,  storms,  floods,  washouts,  sink  holes,  civil  disturbances,
explosions,  breakage  or  accident  to  equipment or machinery, confiscation or
seizure  by  any  government or public authority, nuclear reaction or radiation,
radioactive contamination or other causes, whether of the kind herein enumerated
or  otherwise,  that are not reasonably within the control of the party claiming
the  right  to  delay  performance  on  account  of  such  occurrence.

     23.     No Third-Party Beneficiary.  Any agreement to pay an amount and any
             --------------------------
assumption  of  liability contained in this Agreement, express or implied, shall
be  only  for  the  benefit  of  the  undersigned  parties  and their respective
successors  and assigns (as herein expressly permitted), and such agreements and
assumptions  shall  not inure to the benefit of the obligees or any other party,
whomsoever, it being the intention of the parties hereto that no one shall be or
be  deemed  to  be  a  third-party  beneficiary  of  this  Agreement.

                                       4
<PAGE>
     24.     Law  Governing;  Jurisdiction.  This Agreement shall be governed by
             -----------------------------
and  construed in accordance with the laws of the State of Texas, without regard
to  any  conflicts  of  laws  provisions thereof.  Each party hereby irrevocably
submits to the personal jurisdiction of the United States District Court for the
Southern  District  of  Texas, as well as of the District Courts of the State of
Texas in Harris County, Texas over any suit, action or proceeding arising out of
or  relating  to  this  Agreement.  Each party hereby irrevocably waives, to the
fullest  extent  permitted  by  law, any objection which it may now or hereafter
have to the laying of the venue of any such mediation, arbitration, suit, action
or  proceeding brought in any such county and any claim that any such mediation,
arbitration,  suit, action or proceeding brought in such county has been brought
in  an  inconvenient  forum.

     25.     Incorporation  by Reference.  Any agreement referred to or included
             ---------------------------
herein  constitutes  an integral part to this Agreement and is incorporated into
this  Agreement  by  this  reference.

     26.     Controlling  Agreement.  Other than the provisions of Paragraphs 12
             ----------------------
and 24 hereof, in the event of any conflict between the terms of this Agreement,
the Merger Agreement, or the Other Agreements, the terms of the Merger Agreement
shall  control.

     27.     Multiple  Counterparts.  This  Agreement  may be executed in one or
             ----------------------
more  counterparts,  each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.  A facsimile transmission
or  PDF  copy of this signed Agreement shall be legal and binding on all parties
hereto.

     28.     Entire  Agreement.  This  instrument  contains  the  entire
             -----------------
understanding  of the parties with respect to the subject matter hereof, and may
not  be  changed  orally, but only by an instrument in writing signed by each of
the  parties  hereto.

     IN  WITNESS  WHEREOF, the parties have caused this Agreement to be executed
as  of  the  day  and  year  first  above  written.

                                   MED-X  SYSTEMS,  INC.

                                   By
                                     ------------------------------------------

                                     Hank A. Vanderkam, Chief Executive Officer

                                   EQUITABLE  ASSETS,  INC.

                                   By
                                     ------------------------------------------
                                     Hank  Vanderkam,  Chief Executive Officer

                                   CRANSTON,  INC.  (a  Nevada  corporation)

                                   By
                                     ------------------------------------------
                                     Hank Vanderkam, Chief Executive Officer

                                       5
<PAGE>
                                   CRANSTON, INC. (a New York corporation)

                                   By
                                     ------------------------------------------
                                     Alan  Moadel,  President

                                   GLAST,  PHILLIPS  &  MURRAY,  P.C.

                                   By
                                     ------------------------------------------
                                     Norman  T.  Reynolds

                                       6LICENSE AGREEMENT
                                -----------------

     AGREEMENT made between Wellington Group Holdings Pty Ltd with a mailing
address of 10 Wellington Street. St. Kilda Victoria 3182 Australia (Licensor)
and Cranston Inc., with a mailing address of 14 Bond Street Suite 296, Great
Neck, N.Y. 11021 ("Licensee").

                                    RECITALS
                                    --------

     WHEREAS, Licensee wishes to obtain the right to market a Hair growth
inhibiting formulation ("Formula") along with the use of clinical trial
information ("Clinical Information") associated thereto (collectively, the
"Product") more specifically described in Exhibit A), nationally and
                                          ---------
internationally by direct marketing, infomercial, telephone solicitation, and by
website; and

     WHEREAS, Licensor owns rights to the Product; and has all of the necessary
rights and authority to grant the license which is the subject matter of this
agreement.

     WHEREAS, Licensor is willing to license the Product to the Licensee under
the terms and conditions set forth below.

                                    AGREEMENT
                                    ---------

     NOW THEREFORE in consideration of the mutual promises contained herein and
other good and valuable consideration the sufficiency and adequacy of which is
hereby acknowledged, the parties agree as follows:

     1.     License.  Licensor grants Licensee a license in the Product,
Licensee accepts the license from Licensor.  The License shall include the
following rights and restrictions:

          a.     Licensee will have the exclusive worldwide right to market the
Product nationally and internationally by direct marketing, infomercial,
telephone solicitation, and via Internet sales.

          b.     The parties expressly agree that Licensee shall not have any
right, title, or interest in Licensor's formulas, methodology, empirical data,
or other trade secrets except to the extent provided by this Agreement.

     2.     Fees.  Licensee shall pay to Licensor, a licensing fee ("Fee" or
"Fees") for the license and use of the Product as set forth below.

          a.     Per Unit Basis.  Licensee shall purchase all Product from
Licensor at a $(Confidential Treatment Requested) price per unit. It is
expressly understood by both parties that the licensing fee for Product is
incorporated into the price of Product.

          b.     Minimum quantity.  The minimum order quantity for the initial
order of Product is 10,000 units.  The minimum order quantity for all subsequent
orders is 25,000 units.

          c.     Initial Fee Payment.  Licensee shall pay and deliver to
Licensor, $20,000 (50% of the $40,000 due for the initial order).  The License
set forth herein shall not be deemed effective unless and until Licensor is in
receipt of this $20,000 payment.

          d.     Subsequent Payment for Initial Order.  A subsequent payment of
$20,000 shall be received by Licensor prior to delivering initial order to
Licensee,

          e.     Late Payment, Penalty.  In the event Licensee has not paid Fees
within sixty (60) days of their billing, Licensor or the Certified Manufacturer
may make a demand for fees upon written notice to Licensee. Licensee shall have
fifteen (15) days from the date of written notice to pay such outstanding Fees.
Licensee's failure to pay Fee's after the expiration of fifteen (15) days from
Licensor's written notice shall be cause for Termination as set forth in Section
13.  Licensee agrees that Fees are not subject to any right of counterclaim or

<PAGE>
offset.

          f.     Payment Type - All purchases and payments for product or fees
will be made via wire transfer to the following account:

          Bank Name:     National Australia Bank Limited
          Account Name:  Wellington Group Holdings Pty Ltd
          Account No:    86-595-2254
          Branch No:     023-155

     3.     Term.  The term of this License Agreement will continue so long as
Termination is not declared as set forth in Section 13 herein,

     5.     Use of Clinical Information.  The licensee shall have the
non-exclusive right to use the Clinical Information developed in pilot clinical
trials performed for the Licensor. The use of the Clinical Information is
limited only to the Formula and shall not be used by Licensee with any other
product without the express written consent from Licensor. The Licensor makes no
representations or warranties whatsoever concerning the data derived from tile
clinical trials or any claims whatsoever regarding the Product's performance but
warrants that all trials were legitimately conducted.  The use of clinical trial
data shall be subject to the Licensee's assumption of risk as act forth in
Section 8 of this Agreement.  The use, marketing or application of the Clinical
Information for any other purpose other than for the marketing of the Formula
shall be cause for Termination as set forth in Section 13.

     6.     Protection of Trade Secrets.  "Trade Secret" means other scientific
or technical information, design, process, procedure, formula, or improvement
relating to either the Product, operation or the assets of the Licensor and/or
Certified Manufacturer that is valuable and not generally known to competitors
of the Licensor, including but not limited to, the specialized information and
technology the Licensor may have with respect to the design, manufacture,
capabilities, and performance of the Product or services of the Licensor. The
Licensee hereby acknowledges that the Product contains valuable Trade Secrets of
the Licensee.  The Licensee hereby expressly covenants and agrees that it shall
not reverse engineer or otherwise attempt to discover the Trade Secrets in the
Product for any purpose whatsoever.  The parties acknowledge that no such trade
secrets have been reveled in this document.  The covenant shall survive
indefinitely the termination of this Agreement.  The Licensee acknowledges that
a violation of this covenant would irreparably harm the Licensor and that if it
were violated, the Licensor would not have an adequate remedy at law and that
Licenser shall be entitled to receive an injunction against a breach or
threatened breach of this covenant.

     7.     Non-Competition.  Licensee hereby agrees that it shall not develop a
new or a license another product and market it under the trade name of the
Product, or under a confusingly similar name. The covenant shall survive
indefinitely the (elimination of this Agreement. The Licensee acknowledges that
a violation of this covenant would irreparably harm the Licensor and that if it
were violated, the Licensor would not have an adequate remedy at law, and that
Licensor shall be entitled to receive au Injunction against a breach OT
threatened breach of this covenant.

     8.     Assumption of Risk. The Licensee hereby agrees to hold harmless and
hereby hold harmless the Licensor from any claims the Licensee may make in
regard to Product results including Product results that may arise under the
Clinical Information as set forth in Section 5 of this Agreement, or any other
matters that may be utilized by the Licensee in marketing the Product including
but not limited to sales "puffing."  Any claims Licensee uses to market the
Formula in connection with its sale are its own risk and without recourse to
Licensor.

     8a.     Licensor shall compel the manufacturer of Product to maintain
product liability insurance in the amount of 2 million dollars and shall name
Licensee as an added insured under said policy.

     9.     Confidentiality.  Licensee shall keep confidential all information
regarding the business and affairs of Licensor which it may acquire as a result
of this Agreement and which is not otherwise generally available to the public
("Confidential Information"). Licensee acknowledges and agrees that the
Confidential Information is the exclusive property of Licensor and shall not be
disclosed to the public.  It is further agreed that the existence of this
Agreement shall constitute "Confidential Information" and shall not be disclosed
to any third party.  Each party shall

<PAGE>
make reasonable efforts to prevent their respective agents and employees from
disclosing any Confidential Information.

     This covenant shall survive indefinitely the termination of this Agreement.
The Licensee acknowledges that a violation of this covenant would irreparably
harm the Licensor and that if it were violated the Licensor would not have an
adequate remedy at law. The Licensor shall be entitled to receive an injunction
against a breach or threatened breach of this covenant.

     10.     Choice of Law.  This Agreement shall be construed in accordance
with the Laws of the State of Maine.

     11.     Jurisdiction and Venue. The parties to this Agreement agree to
submit to the jurisdiction of the state and federal courts of the States of
Maine or any jurisdiction where the Licensor maintains its records

     12.     Non-Assignment.

          a.     No Assignment.  It is agreed that none of the rights of
Licensee provided for in this Agreement are transferable or assignable without
the prior, express, written consent of Licensor.  Licensor may not unreasonably
withhold consent to any assignment.  Any purported assignment without the
consent of Licensor shall be null and void.

          b.     No Sub-License.  It is agreed that Licensee shall have no right
to sub-license the License granted under this Agreement without the prior,
express, written consent of Licensor.  Licensor may not unreasonably withhold
consent to a sub-license.

          c.     Licensor Agreement.  It is agreed that the Licensor may assign
its rights set forth in this agreement at any time during the term of the
agreement.

     13.     Termination.

          a.     Breach.  In the event of a breach or other non-performance of
the terms of this Agreement, this Agreement shall terminate upon fifteen (15)
days within notice of termination from Licensor to Licensee.  Licensee shall
have fifteen (15) days to cure any failure to meet the terms of this Agreement.

          b.     Bankruptcy or Insolvency.  Either party hereto may terminate
this Agreement for cause if the other party hereto becomes the subject of a
voluntary or involuntary petition in bankruptcy or any proceeding related to the
insolvency, receivership, liquidation or composition for the benefit of
creditors.

          c.     Unpaid Fees.  In the event of the termination of this
Agreement, Licensee shall be responsible for payment of all Fees accrued prior
to the date of Termination.  In the event Licensee's breach shall derive from
the failure to meet minimum purchases, Licensor's sole remedy shall be to
terminate this license.  Licensee shall remain responsible for all goods
received and on order, but shall not be liable for any shortfall below the
minimums set forth elsewhere herein.  Applicable penalties for delay in payment
shall apply.

          d.     Survival.  In the event of the termination of this Agreement,
the obligations pursuant to Section 6 (Protection of Trade Secrets), Section 7
(Non-Competition), Section 8 (Assumption of Risk), and Section 9
(Confidentiality) shall survive indefinitely termination of this Agreement or in
accordance with the survival terms set forth individually in those sections.

     14.     Miscellaneous.

          a.     Non-Waiver. A failure by Licensor to exercise any right
hereunder, or otherwise waive or condone any delay or failure by Licensee to
comply with any of the terms and conditions of this Agreement shall not
constitute a continuing waiver of any such requirement or provision of any of
the rights of Licensor pursuant to this Agreement.

<PAGE>
          b.     Severability.  If any portion of this Agreement shall be
construed to be illegal or invalid by a court of competent jurisdiction such
construction shall not affect the legality or validity of any of the provisions
hereof, and the illegal or invalid provisions will be deemed stricken and
deleted herefrom to the same extent and effect as if never incorporated herein,
but all other provisions hereof shall continue in full force and effect.

          c.     Amendment.  This agreement shall not be altered or amended
except in writing executed by the parties.

          d.     Notices.  All notices under this Agreement shall be sent by
certified mail, return receipt requested to the address given below or to such
other addresses as either party may designate in writing to the other.

     To Licensor:     Wellington Group Holdings Pty Ltd
                      10 Wellington Street.
                      St. Kilda Victoria 3182
                      Australia
     To Licensee:     Cranston, Inc.
                      14 Bond Street Suite 296,
                      Great Neck. N.Y. 11021
                      USA

          e.     Counterparts.  This Agreement may be executed in any number of
identical counterparts, each of which will be considered an original, but all of
which taken together will constitute one and the same instrument.

          f.     Entire Agreement.  The terms and conditions herein contained
the entire Agreement between the parties with respect to the subject matter of
this Agreement and supersedes other previous agreements and understandings,
whether oral or written, between the parties hereto with respect to the subject
matter hereof, except as stated in this Agreement there are no other agreements,
understandings, representations or promises between the parties with respect to
the subject matter of this Agreement.

IN WITNESS WHEREOF the parties have set their bands.

Dated: November 21, 2006
                                        LICENSOR:

                                        Wellington Group Holdings Pty Ltd
                                        By:
                                           ----------------------------------
--------------------------------
Witness                                        Its:

                                        LICENSEE:

                                        Cranston, INC.
                                        By:
                                           ---------------------------------

--------------------------------
Witness

<PAGE>
                                    EXHIBIT A
                                    ---------

"Formula":
Shave Less contains (by weight):
Distilled water (Confidential Treatment Requested)%
Glycerol (Confidential Treatment Requested)%
Propylene glycol (Confidential Treatment Requested)%
Sucrose (Confidential Treatment Requested)%
Herbal Extract (Confidential Treatment Requested)%
Avocado Oil (Confidential Treatment Requested)%
Lactic Acid (Confidential Treatment Requested)%
Grapefruit peel extract (Confidential Treatment Requested)%
Chamomile extract (Confidential Treatment Requested)%
Betaglucan (Confidential Treatment Requested)%
Propylparaben (preservative) (Confidential Treatment Requested)%
Methylparaben (preservative) (Confidential Treatment Requested)%
EDTA (Confidential Treatment Requested)%

One spray is approximately equal to 0.1 ml.  The active ingredients are
glycerol, propylene glycol, sucrose, avocado oil, lactic acid, grapefruit peel,
chamomile, oat betaglucen, and EDTA.  The inactive ingredients are proylparaben,
methylparaben, and water.

The formulation is the property of Wellington Group Holdings Pty Ltd. Propriety
blends are confidential.

"Clinical Information": shall mean all data, reports, writings, research, and
calculations performed by Healthcare Choreography, LLC d/b/a Marshal - Blum to
the Formula.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]